Related Experiment Video
Updated: Dec 13, 2025
Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer
Published on: September 8, 2023
Small Cell Lung Cancer from Traditional to Innovative Therapeutics: Building a Comprehensive Network to Optimize
Shanmuga Subbiah1, Arin Nam1, Natasha Garg1
1Department of Medical Oncology and Therapeutics Research, City of Hope National Medical Center, Duarte, CA 91010, USA.
Abstract:
Small cell lung cancer (SCLC) is an aggressive, complex disease with a distinct biology that contributes to its poor prognosis. Management of SCLC is still widely limited to chemotherapy and radiation therapy, and research recruitment still poses a considerable challenge. Here, we review the current standard of care for SCLC and advances made in utilizing immunotherapy. We also highlight research in the development of targeted therapies and emphasize the importance of a team-based approach to make clinical advances. Building an integrative network between an academic site and community practice sites optimizes biomarker and drug target discovery for managing and treating a difficult disease like SCLC.
Insights
Small cell lung cancer (SCLC) treatment remains challenging, primarily using chemotherapy and radiation. Advances in immunotherapy and targeted therapies, alongside collaborative research networks, are crucial for improving patient outcomes.
Area of Science:
- Oncology
- Medical Research
Background:
- Small cell lung cancer (SCLC) is an aggressive malignancy with a poor prognosis.
- Current treatment options for SCLC are limited, primarily relying on chemotherapy and radiation therapy.
- Research recruitment for SCLC clinical trials presents significant challenges.
Purpose of the Study:
- To review the current standard of care for SCLC.
- To discuss recent advances in immunotherapy for SCLC treatment.
- To highlight the development of targeted therapies and the importance of collaborative research networks.
Main Methods:
- Literature review of current SCLC management strategies.
- Analysis of recent clinical trial data and research findings on immunotherapy and targeted therapies.
- Discussion of the role of integrated research networks in advancing SCLC treatment.
Main Results:
- Chemotherapy and radiation remain the cornerstone of SCLC care.
- Immunotherapy shows promise in improving SCLC treatment outcomes.
- Targeted therapy development is an active area of research.
- Collaborative networks enhance biomarker and drug target discovery.
Conclusions:
- Advances in immunotherapy and targeted therapies offer new hope for SCLC patients.
- A multidisciplinary, team-based approach is essential for clinical progress in SCLC.
- Integrated academic and community research networks are vital for optimizing SCLC management and treatment discovery.
Related Concept Videos
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
02:49Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
02:50Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...